Clinical Trials · NCT01293292

Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action

CompletedPhase 4Teriparatide (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
Sheffield Teaching Hospitals NHS Foundation Trust
Enrollment
19
Start date
Jan 2011
Locations
1 site, United Kingdom
Primary endpoint
Volumetric bone mineral density (BMD) of the lumbar spine (mg hydroxyapatite/cm3)
View Teriparatide compound reference